Compass Wealth Management’s AstraZeneca AZN Stock Holding History

Compass Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-32	Closed	-$4.44K	–	409
2023 Q1	$4.44K	Hold	32	–	–	﹤0.01%	389
2022 Q4	$4.34K	Buy	+32	New	+$4.01K	﹤0.01%	385

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Compass Wealth Management's AZN Position: Q2 2023 in Review

Compass Wealth Management sold out of AstraZeneca (AZN) in Q2 2023, closing a stake of 32 shares — an estimated $4.44K sold.

Compass Wealth Management first reported a position in AZN in Q4 2022 and held it in 2 quarters. The position peaked at $4.44K in Q1 2023. 1,090 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

Compass Wealth Management reported no remaining AstraZeneca position as of Q2 2023 after selling out during the quarter.
Compass Wealth Management sold 32 AstraZeneca shares in Q2 2023, an estimated $4.44K.
Compass Wealth Management first reported a position in AstraZeneca in Q4 2022 and held it in 2 quarters.
Compass Wealth Management's AstraZeneca position peaked at $4.44K in Q1 2023.
1,090 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on Compass Wealth Management's 13F filing for Q2 2023, filed 21 Jul 2023.